May 09, 2022
Brii Bio Announces Positive Data Demonstrating its Long-Acting COVID-19 Neutralizing Antibody Therapy, Amubarvimab/Romlusevimab Combination, Retains Neutralizing Activity Against Omicron BA.2 Subvariant
May 07, 2022
Brii Bio Reports Progress on ESG Commitments in Its Inaugural ESG Report
